DV
Dividend Vision

GRFS — Grifols SA ADR

Grifols SA ADR (GRFS)

GRFS pays a 1.21% distribution rate. Its Distribution Safety Score™ is 38 (Elevated risk), giving a Safety-Adjusted Yield of 0.46%. Total return is 30.0% over the past 15.2 years, 641.1 points behind SPY at 671.1%. Its deepest 1-year drawdown was 34.1%.

Grifols is a Spain-based biopharmaceutical company that researches, develops, and markets plasma-derived medicines for treating immunology, infectious diseases, and other conditions, alongside diagnostic testing equipment and healthcare solutions for hospitals. The company operates through four business segments—Biopharma, Diagnostic, Bio Supplies, and Others—serving customers across the United States, Canada, Europe, and internationally. It offers a modest current distribution rate and may appeal to income-focused investors seeking exposure to the pharmaceutical and healthcare sectors.

GRFS key facts

Distribution Safety Score™
38 · Elevated risk
Safety-Adjusted Yield
0.46%
Asset type
Stock
Asset class
Equity
Inception date
06/02/2011
Distribution rate
1.21%
Trailing yield
1.21%
5-year average yield
2.4
Last close
$7.78
Market cap
$4,947,812,352
Average volume
264900.0
Last dividend
$0.0940
Ex-dividend date
07/02/2026
Payment date
07/09/2026
Beta
1.178
Payout ratio
0.3158
P/E ratio
10.5362
Forward P/E
8.4034
EPS
$0.69